Aquestive Therapeutics Inc
NASDAQ:AQST
Aquestive Therapeutics Inc
Long-Term Debt
Aquestive Therapeutics Inc
Long-Term Debt Peer Comparison
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/jnj.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/bmy.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/pfe.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/mrk.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/lly.png)
Competitive Long-Term Debt Analysis
Latest Figures & CAGR of Competitors
Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
A
|
Aquestive Therapeutics Inc
NASDAQ:AQST
|
Long-Term Debt
$28.8m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
![]() |
Johnson & Johnson
NYSE:JNJ
|
Long-Term Debt
$25.1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
7%
|
![]() |
Bristol-Myers Squibb Co
NYSE:BMY
|
Long-Term Debt
$49.5B
|
CAGR 3-Years
4%
|
CAGR 5-Years
54%
|
CAGR 10-Years
21%
|
![]() |
Pfizer Inc
NYSE:PFE
|
Long-Term Debt
$61.3B
|
CAGR 3-Years
20%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
![]() |
Merck & Co Inc
NYSE:MRK
|
Long-Term Debt
$31.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
![]() |
Eli Lilly and Co
NYSE:LLY
|
Long-Term Debt
$24.6B
|
CAGR 3-Years
15%
|
CAGR 5-Years
13%
|
CAGR 10-Years
17%
|
See Also
What is Aquestive Therapeutics Inc's Long-Term Debt?
Long-Term Debt
28.8m
USD
Based on the financial report for Mar 31, 2024, Aquestive Therapeutics Inc's Long-Term Debt amounts to 28.8m USD.
What is Aquestive Therapeutics Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
-7%
Over the last year, the Long-Term Debt growth was 14%. The average annual Long-Term Debt growth rates for Aquestive Therapeutics Inc have been -6% over the past three years , -7% over the past five years .